Novel therapies

for inflammatory diseases

We are a clinical-stage biopharma company

Abcentra is leveraging cutting-edge science to develop a portfolio of novel antibody therapeutics for serious inflammatory diseases where new treatments are critically needed.

Bullseye Icon

Target Inflammation

Our products target oxidized low-density lipoprotein (oxLDL), an inflammatory mediator that is implicated in inflammatory diseases including psoriasis, rheumatoid arthritis, cardiovascular disease and cancer.

How It Works

Antibody icon

Treat Disease

Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.

Learn More